In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent

Drug Metabolism and Disposition

Volumn 27, Issue 2, 1999, Pages 250-254

  Nicolas, Jean Marie ^a   Collart, Philippe ^a   Gerin, Brigitte ^a   Mather, Gary ^b   Trager, William ^b   Levy, Rene ^b   Roba, Jose ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; 7 ETHOXYCOUMARIN DEETHYLASE; ANTICONVULSIVE AGENT; BETA NAPHTHOFLAVONE; COUMARIN; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DEXAMETHASONE; DEXTROMETHORPHAN; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLITE; EPOXIDE HYDROLASE; ETHINYLESTRADIOL; ETIRACETAM; GLUCURONOSYLTRANSFERASE; MEPHENYTOIN; PARACETAMOL; PHENACETIN O DEETHYLASE; PHENOBARBITAL; PHENYTOIN; TESTOSTERONE; TOLBUTAMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; WARFARIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; BIOLOGICAL MARKERS; BUTYRIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MALE; MICROSOMES, LIVER; PIRACETAM; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0032963256     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Arlotto MP, Trant JM and Estabrook RW (1991) Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods Enzymol 206:454-462.
2. Bars RG, Mitchell AM, Wolf CR and Elcombre CR (1989) Induction of cytochrome P-450 in cultured rat hepatocytes. The heterogeneous localization of specific isoenzymes using immunocytochemistry. Biochem J 262:125-158.
3. Bianchetti G, Padovani P, Thenot JP, Thiercelin JF and Morselli PL (1987) Pharmacokinetic interactions of progabide with other antiepileptic drugs. Epilepsia 28:68-73.
4. Burchell B and Weatherill P (1981) 4-Nitrophenol UDP-glucuronyltransferase (rat liver) Methods Enzymol 77:169-177.
5. Burchell B, Brierley CH and Ranee D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57:1819-1831.
6. Bush ED, Low LK and Trager WF (1983) A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed Mass Spectrom 10:395-398.
7. Cotariu D and Zaidman JL (1988) Valproic acid and the liver. Clin Chem 34:890-897.
8. Edwards AM, Glistak ML, Lucas CM and Wilson PA (1984) 7-Ethoxycoumarin deethylase activity as a convenient measure of liver drug metabolizing enzymes: Regulation in cultured rat hepatocytes. Biochem Pharmacol 33:1537-1546.
9. FDA (1995) Memorandum of understanding between the Food and Drug Administration and the National Institutes of Health. Fed Reg 60:21214-21215.
10. Fleishaker JC, Pearson LK and Peters GR (1995) Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci 84:292-294.
11. Goldstein JA, Faletto MB, Romkes-Sparks R, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
12. Hermodson MA, Barker WM and Link KP (1971) Studies of the 4-hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J Med Chem 14:167-169.
13. Ho JW and Moody DE (1992) Determination of tolbutamide hydroxylation in rat liver micro-somes by high-performance liquid chromatography: Effect of psychoactive drugs on in vitro activity. Life Sci 52:21-28.
14. Kerr MB, Rettie AE, Eddy AC, Loiseau P, Guyot M, Wilenski AJ and Levy R (1989) Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin Pharmacol Ther 46:82-93.
15. Klitgaard H, Matagne A, Gobert J and Wülfert E (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191-206.
16. Kremers P, Beaune P, Cresteil T. De Graeve J, Columelli S, Leroux J-P and Gielen J (1981) Cytochrome P-450 monooxygenase activities in human and rat liver microsomes. Eur J Biochem 118:599-606.
17. Kroetz DL, Loiseau P, Guyot M and Levy R (1993) In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther 54:485-497.
18. Levy RH (1995) Cytochrome P-450 isoenzymes and antiepileptic drug interactions. Epilepsia 36:S8-S13.
19. Lowry OH, Rosebuigh NJ, Fair AL and Randall AJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265-272.
20. Mather GG and Levy RH (1996) Pharmacokinetics of polypharmacy: Prediction of drug interactions. Epilepsy Res 2 (Suppl.):113-122.
21. Mawer GE and Pleuvry BJ (1995) Interactions involving new antiepileptic drugs. Pharmacol Ther 68:209-231.
22. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA and Wolf CR (1990) Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371.
23. Nims RW, McClain RM, Manchand PS, Belica PS, Thomas PE, Mellini DW, Utermahlen WE and Lubet RA (1994) Comparative pharmacodynamics of hepatic cytochrome P450 2B induction by 5.5-diphenyl- and 5.5-diethyl-substituted barbiturates and hydantoins in the male F344/NCr rat. J Pharmacol Exp Ther 270:348-355.
24. Pacifici GM and Back DJ (1988) Sulphatation and glucuronidation of ethinyloestradiol in human liver in vitro. J Steroid Biochem 31:345-349.
25. Pacifici GM, Back DJ and Orme ML (1988) Sulfatation and glucuronidation of paracetamol in human liver: Assay conditions. Biochem Pharmacol 37:4405-4407.
26. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45-57.
27. Patsalos PN and Duncan JS (1993) Antiepileptic drugs. A review of clinically significant drug interactions. Drug Safety 9:156-184.
28. Patsalos PN and Sander JWAS (1994) Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Safety 11:37-67.
29. Perucca E (1987) Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 33:139-144.
30. Pichard L, Fabre I, Fabre G, Momergue J, Saint Aubert B, Mourad G and Maurel P (1990) Cyclosporin A drug interactions. Drug Metab Dispos 18:595-606.
31. Pisani F (1992) Influence of co-medication on the metabolism of valproate. Pharm Weekbl 14:108-113.
32. Ratnaraj N, Doheny HC and Patsalos PN (1996) A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromalography. Ther Drug Monit 18:154-157.
33. Sadeque AJM, Korzekwa KR, Gonzalez FJ and Rettie AE (1995) Identification of human liver cytochrome P450 isoenzymes responsible for the formation of 4-ene valproic acid. Fourth International ISSX meeting, poster communication; 1995 August 27-31; Seattle, WA.
34. Seglen PU (1976) Preparation of isolated rat liver cells. Methods Cell Biol 18:29-83.
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
36. Tassaneeyakul W, Veronese ME, Birkett DJ and Miners JO (1993) High-performance liquid Chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P4502E1 activity, in human liver microsomes. J Chromatogr 616:73-78.
37. Thummel KE, Kharasch ED, Podoll T and Kunze K (1993) Human liver microsomal enflurance defluorination catalysed by P-450 2E1. Drug Metab Disp 21:350-357.
38. West BD, Preis S. Schroeder CH and Link KP (1961) Studies on the 4-hydroxycoumarins. XVII. The resolution and absolute configuration of warfarin. J Am Chem Soc 83:2676-2679.
39. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE and Trager W (1996) Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Disp 24:610-614.
40. Wortelboer HM, DeKruif CA, van Iersel AAJ, Falke HE, Noordhoek J and Blaauboer BJ (1991) Comparison of cytochrome P450 isoenzyme profiles in rat liver and hepatocyte cultures. The effects of models inducers on apoproteins and biotransformation activities. Biochem Pharmacol 42:381-391.
41. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W and Sellers EM (1993) Inhibition of human cytochrome P450 2D6(CYP2D6) by methadone. Br J Clin Pharmacol 35:30-34.
42. Zhang SZ, Lipsky MM, Trump BF and Hsu IC (1990) Neutral red (NR) assay for cell viability and xenobiotic-induced cytotoxicity in primary cultures of human and rat hepatocytes. Cell Biol Toxicol 6:219-234.